- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | HCW Biologics jumps 16% on pricing $5M follow on offering | 1 | Seeking Alpha | ||
| Mi | HCW Biologics Inc.: HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules | 1 | GlobeNewswire (USA) | ||
| Di | HCW Biologics Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| Di | HCW Biologics präsentiert neuartigen CAR-T-Zell-Verstärker | 5 | Investing.com Deutsch | ||
| Di | HCW Biologics presents novel CAR-T cell enhancer | 2 | Investing.com | ||
| HCW BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| Di | HCW Biologics Inc.: HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization | 85 | GlobeNewswire (Europe) | Addresses key challenges for CAR-T therapies Potential to significantly reduce costs and improve clinical efficacy of engineered effector T cells Data Shared at 2025 Annual Meeting of American Association... ► Artikel lesen | |
| Fr | HCW Biologics Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 22.04. | HCW Biologics Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 14.04. | HCW Biologics Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 07.04. | HCW Biologics Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 02.04. | Antelope Enterprise, HCW Biologics Announce 1-for-40 Reverse Stock Split; Shares Down | - | RTTNews | ||
| 01.04. | HCW Biologics approves reverse stock split to meet Nasdaq rules | 3 | Investing.com | ||
| 01.04. | HCW Biologics genehmigt Aktienzusammenlegung zur Erfüllung der NASDAQ-Vorschriften | 4 | Investing.com Deutsch | ||
| 01.04. | HCW Biologics, Inc: HCW Biologics Announces 1-for-40 Reverse Stock Split | 154 | GlobeNewswire (Europe) | MIRAMAR, Fla., April 01, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing... ► Artikel lesen | |
| 28.03. | HCW Biologics GAAP EPS of -$0.08 misses by $0.17, revenue of $0.39M misses by $6.61M | 4 | Seeking Alpha | ||
| 28.03. | HCW Biologics Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 28.03. | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.03. | HCW Biologics, Inc: HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results | 689 | GlobeNewswire (Europe) | MIRAMAR, Fla., March 28, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing... ► Artikel lesen | |
| 19.03. | HCW Biologics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.03. | HCW Biologics, Inc: HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements | 153 | GlobeNewswire (Europe) | MIRAMAR, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (Nasdaq: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing... ► Artikel lesen |
Seite:
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 0,100 | +35,49 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 08.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 08.05.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 08.05.2025.ISIN NameGB00BYQ94H38 ONCIMMUNE... ► Artikel lesen | |
| BIOXXMED | 0,410 | 0,00 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
| VIVOSIM LABS | 1,930 | +1,05 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
| OCUGEN | 0,629 | +0,74 % | Ocugen Provides Business Update with First Quarter 2025 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing well and on target for potential BLA/MAA filings by mid-2026Anticipate... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
| BIO-GATE | 0,685 | 0,00 % | Bio-Gate startet Produkt-Launch für Tierpflege in den USA | Bio-Gate hat die Präsenz im nordamerikanischen Veterinärmarkt ausgebaut. Gemeinsam mit einem internationalen Anbieter bringt Bio-Gate neue Tierpflegeprodukte zur Haut-, Ohr- und Wundbehandlung in die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,574 | -3,37 % | Evotecs KI-Goldgrube, Defence Therapeutics Milliarden-Märkte, Novo Nordisks Diät-Revolution: So verdienen Anleger mit | Die Gesundheitsbranche befindet sich im Umbruch. Algorithmen beschleunigen die Arzneimittelforschung um Jahre, Milliarden fließen in personalisierte Therapien, und Börsen feiern Biotech-Aktien. Doch... ► Artikel lesen | |
| VAXART | 0,369 | +1,15 % | Vaxart, Inc.: Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial | SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has received approval from the Biomedical Advanced Research and Development Authority... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 0,063 | -1,56 % | Burcon NutraScience Corporation: Burcon Integrates Protein Technologies at Galesburg Facility | Vancouver, British Columbia--(Newsfile Corp. - April 1, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development of... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 0,206 | -4,63 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update | Company Seeking Conditional Approval from European Medicines Agency (EMA) for Iopofosine I 131 in Waldenstrom Macroglobulinemia based upon CLOVER WaM Phase 2 Study Data CLOVER WaM Major Response Rate... ► Artikel lesen | |
| AFFIMED | 0,530 | -100,00 % | Affimed N.V.: Affimed Announces Receipt of Nasdaq Delisting Notice | MANNHEIM, Germany, May 14, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists | ||
| IMMUNIC | 0,871 | -0,57 % | EQS-News: Immunic AG: Immunic to Participate in Scientific and Industry Conferences in May | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Scientific and Industry Conferences in May
02.05.2025 / 12:30 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,107 | +3,38 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
| CEL-SCI | 0,217 | 0,00 % | Cel-Sci GAAP EPS of -$0.08 |
HCW BIOLOGICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,810 (-8,99 %) liegt der Kurs bei 8,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HCW BIOLOGICS INC finden Sie auf Wallstreet Online.